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ABSTRACT
Objectives Lower gastrointestinal symptoms are not 
well characterized in people with type 1 diabetes, and the 
effects on quality of life and glycemic control are unknown. 
This study aimed to determine the prevalence of lower 
gastrointestinal symptoms and the effects on glycemic 
control and quality of life, and to investigate for underlying 
causes.
Research design and methods This is a prospective, 
cohort study in secondary care. Patients with type 
1 diabetes completed a gastrointestinal symptom 
questionnaire and the Short Form 36 V.2 quality of life 
questionnaire and had their hemoglobin A1c measured. 
Patients with diarrhea were offered reassessment and 
investigation as per the national guidelines. Controls 
without diabetes were used to compare symptom 
prevalence and quality of life scores.
Results  706 with type 1 diabetes (mean age 41.9 
years) and 604 controls (mean age 41.9 years) were 
enrolled. Gastrointestinal symptoms were significantly 
more frequent in type 1 diabetes compared with controls, 
in particular constipation (OR 2.4), diarrhea (OR 2.5), 
alternating bowel habit (OR 2.1), abdominal pain (OR 
1.4), floating stools (OR 2.7), bloating (OR 1.4) and 
flatulence (OR 1.3) (all p<0.05). Previous pancreatitis 
was more frequent in type 1 diabetes (OR 4.6), but other 
gastrointestinal conditions were not. Gastrointestinal 
symptoms were associated with poorer glycemic control 
(p<0.01) and worse quality of life particularly in those with 
diarrhea. Investigation of those with diarrhea, including 
those with alternating bowel habit, (n=105), identified a 
cause in 72.3% with subsequent change in management.
Conclusions Gastrointestinal symptoms are twice as 
common in type 1 diabetes and associated with poorer 
quality of life and glycemic control. Investigation of 
diarrhea in people with type 1 diabetes leads to a high 
yield of treatable conditions and a change in management 
in about three-quarters.
InTROduCTIOn
Long-term complications cause major 
morbidity and mortality in type 1 diabetes 
mellitus.1 Intensive glycemic control can 
reduce long-term complications and improve 
quality of life.1 2 Even with good glycemic 
control, complications occur, suggesting 
other factors increase the risk.3 Coex-
isting medical problems are a significant 
confounding factor when managing patients’ 
glycemic control.3 The association between 
type 1 diabetes and the gastrointestinal tract 
was first described in 1936 by Bargen.4 Classi-
cally, this has been described as diabetic diar-
rhea and most commonly occurs in patients 
with type 1 diabetes mellitus.4 Despite this 
historical description there have been very 
few studies examining patients with type 1 
diabetes specifically for lower gastrointestinal 
symptoms.
A postal survey of 15 000 people from 
Australia suggested that patients with diabetes 
are more likely to have gastrointestinal symp-
toms than the general population. Critically, 
although the survey comprises an initial 
attempt to question 15 000 individuals, there 
was a 60% response (n=8657) and only 27 of 
the respondents had type 1 diabetes. Further-
more, glycemic control and gastrointestinal 
Significance of this study
What is already known about this subject?
 ► Gastrointestinal symptoms occur in people with 
diabetes, but the true prevalence is unknown and 
the underlying causes of diarrhea in diabetes are not 
well characterized.
What are the new findings?
 ► Lower gastrointestinal symptoms are twice as com-
mon in people with diabetes and are associated with 
worse glycemic control and quality of life.
 ► Focused investigations lead to treatable causes in 
over two-thirds of those with diarrhea.
How might these results change the focus of 
research or clinical practice?
 ► A low threshold for investigating gastrointestinal 
symptoms in people with type 1 diabetes may lead 
to improvement in glycemic control and quality of 
life.
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symptoms were self-reported and no investigations were 
performed.5 Despite these limitations this study reported 
that both upper and lower gastrointestinal symptoms 
were significantly more common in patients with 
diabetes compared with controls.5 A further study found 
that gastrointestinal symptoms in patients with diabetes 
were associated with poor glycemic control (glycosylated 
hemoglobin was measured in a subgroup) and periph-
eral neuropathy.6 This group has subsequently suggested 
no association between glycemic control and gastroin-
testinal symptoms.7 This study only included 136 indi-
viduals of whom a minority (n=7) had type 1 diabetes 
and glycemic control was self-reported. The concept of 
gastrointestinal symptom cycling in patients with diabetes 
has been proposed and is associated with psychological 
factors rather than glycemic control.8 
There is a paucity of data regarding gastrointestinal 
symptoms in patients with type 1 diabetes, in partic-
ular regarding prevalence, underlying causes and 
pathophysiology.
Several mechanisms have been implicated in the 
pathogenesis of gastrointestinal symptoms, including 
Helicobacter pylori infection,9 psychological factors,10 and 
impaired sensory function.11 12 However, disordered 
motor function resulting from autonomic neurop-
athy13 14 and abnormal blood glucose levels also seem to 
be important. Acute changes in blood glucose concentra-
tions can have an effect on motor function throughout 
the gastrointestinal tract15 16 and modulate sensory 
perception.17–20 An association between gastrointestinal 
symptoms and glycemic control is also supported by 
cross-sectional epidemiologic studies.6 21 
The mechanism by which diabetes may lead to diar-
rhea is thought to be multifactorial, and most hypotheses 
include autonomic dysfunction and alteration of regula-
tory enterohumoral responses.22 Type 1 diabetes is also 
associated with a number of conditions which could lead 
to diarrhea, including celiac disease,23 exocrine pancre-
atic insufficiency,24 thyroid dysfunction,25 IgA deficiency26 
and small bowel bacterial overgrowth.27 Although these 
associations have been independently reported, there 
has never been a unifying assessment of a large cohort of 
patients with type 1 diabetes and diabetic diarrhea.
This area deserves investigation as gastrointestinal 
symptoms are likely to impact on quality of life and 
glycemic control. The aims of this study were to determine 
the prevalence of gastrointestinal symptoms in patients 
with type 1 diabetes and to determine the correlation 
between such symptoms, glycemic control and quality of 
life. Furthermore, a subgroup with significant diarrhea 
was investigated to determine underlying causes.
ReseaRCH desIgn and meTHOds
The Sheffield Diabetes Centre operates at the Royal 
Hallamshire Hospital and the Northern General 
Hospital, Sheffield, UK, comprising approximately 2000 
patients registered with a diagnosis of type 1 diabetes. 
Type 1 diabetes was defined as per the American Diabetes 
Association position statement.28 Therefore patients were 
considered to have type 1 diabetes if they presented at 
an early age, with diabetic ketoacidosis or progressed 
onto insulin within 12 months. If autoantibody profiles 
were available, then these were also considered. Where 
diabetes type was uncertain, the notes were reviewed with 
the treating physician and a decision made concerning 
diabetes type. If diabetes type was still uncertain, then the 
individual was not invited to participate.
Inclusion criteria
The study includes patients with type 1 diabetes over the 
age of 16 years.
exclusion criteria
The exclusion criteria include age of less than 16 years 
and inability to give consent.
Initial assessment
Participants completed a previously validated gastroin-
testinal symptom questionnaire which has been used in 
local studies29 to assess the presence and degree of symp-
toms, as well as document other relevant diagnoses. Diar-
rhea was defined as greater than three stools per day and 
constipation as less than three stools per week as per the 
British Society of Gastroenterology guidelines.30 Quality 
of life was assessed using the Short Form 36 V.2 question-
naire and blood was taken for hemoglobin A1c (HbA1c).
Control group
During the same time period a control group was 
recruited from the general population and the same 
questionnaires were completed. These individuals were 
recruited from local shopping centers and supermar-
kets during daylight hours. This group was selected to 
compare with type 1 diabetes as the majority seen as 
outpatients for diabetes review are able-bodied.
Investigations for subgroup with diarrhea
Individuals with type 1 diabetes and diarrhea (including 
those with alternating bowel habits) were recalled and 
offered investigation. All individuals underwent a stan-
dard protocol of investigations, including celiac serology 
(and duodenal biopsy in positive cases), fecal elastase-1 
measurement, glucose hydrogen breath testing and ileo-
colonoscopy. Individuals with positive findings on investi-
gation were reviewed and relevant treatment was started.
Statistical analysis
The frequency of gastrointestinal symptoms in individ-
uals with type 1 diabetes was compared with the controls 
and was expressed as ORs with 95% CIs. Frequencies were 
compared using χ2 testing or Fisher’s exact if n<10 in any 
category. Glycemic control was assessed using median 
HbA1c in those with type 1 diabetes with symptoms 
compared with age-matched and sex-matched controls 
with type 1 diabetes but no symptoms. The median 
quality of life scores in those with type 1 diabetes and 
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Table 1  Clinical characteristics of participants with type 
1 diabetes mellitus
Variable Type 1 diabetes
Mean age 41.9 years (95% CI 39.8 to 
44.0)
Number of men 390/706 (55.2%)
Mean hemoglobin A1c 8.27 (SD 1.68)
Self-reported complications (%) 
  Retinopathy 249 (35.3)
  Nephropathy 55 (7.8)
  Peripheral neuropathy 133 (18.8)
Table 2  Prevalence of gastrointestinal symptoms and known medical conditions in people with type 1 diabetes and 
comparison with controls
Symptom Type 1 diabetes Controls OR (95% CI) P values
Normal bowel habit 541 (76.6%) 540 (89.4) 0.4 (0.3 to 0.6) <0.001
Constipation 60 (8.5%) 20 (3.3%) 2.4 (1.4 to 4.1) <0.001
Diarrhea 43 (6.1%) 16 (2.6%) 2.5 (1.4 to 4.5) 0.0017
Alternating bowel habit 62 (8.8%) 27 (4.5%) 2.1 (1.3 to 3.4) 0.0013
Flatulence 231 (34.9%) 174 (28.8%) 1.3 (1.0 to 1.7) 0.02
Bloating 203 (30.7%) 146 (24.2%) 1.4 (1.1 to 1.8) 0.009
Floating stools 84 (12.7%) 31 (5.1%) 2.7 (1.8 to 4.1) <0.001
Weight loss 76 (11.5%) 34 (5.6%) 2.2 (1.4 to 3.3) 0.0002
Abdominal pain 117 (17.7%) 81 (13.4%) 1.4 (1.0 to 1.9) 0.037
TATT 247 (37.3%) 100 (16.6%) 3.0 (2.3 to 3.9) <0.001
Celiac disease 2 4 0.4 (0.1 to 2.3)   NS
Anemia 92 53 1.5 (1.1 to 2.2) 0.012
Thyroid 87 20 4.1 (2.5 to 6.8) <0.0001
Primary biliary cirrhosis 1 0 NA   NS
Sjogren’s 2 0 NA   NS
Dermatitis herpetiformis 3 0 NA   NS
Osteoporosis 15 12 1.1 (0.5 to 2.3)   NS
Epilepsy 15 3 4.3 (1.3 to 15.1) 0.015
Neurologic disease 29 11 2.3 (1.1 to 4.7) 0.023
Previous pancreatitis 16 3 4.6 (1.3 to 16.0) 0.0009
Irritable bowel syndrome 74 48 1.4 (0.9 to 2.0)   NS
Diverticular disease 5 4 1.1 (0.3 to 4.0)   NS
Inflammatory bowel disease 8 2 3.4 (0.7 to 16.3)   NS
Bowel cancer 1 5 0.2 (0.02 to 1.5)   NS
Other 35 16 1.9 (1.1 to 3.5) 0.032
Appendectomy 67 46 1.3 (0.9 to 1.9)   NS
Tonsillectomy 116 104 1 (0.7 to 1.3)   NS
NA, not applicable; TATT, tiredness all the time.
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symptoms were compared with the age-matched and 
sex-matched individuals with type 1 diabetes and no 
symptoms. Additionally, controls without diabetes with 
the same symptoms and controls with no symptoms were 
age-matched and sex-matched to these individuals with 
type 1 diabetes. The Kruskal-Wallis test, and if significant 
the Mann-Whitney U test, was applied.
ResulTs
Seven hundred and six participants with type 1 diabetes 
(mean age 41.9 years, 95% CI 39.8 to 44.0, 390 men) and 
604 controls without diabetes (mean age 41.9 years, 95% 
CI 40.5 to 43.4, 279 men) were included (characteristics 
are shown in table 1).
Overall 440/706 (62.3%, 95% CI 58.6 to 65.9) individ-
uals with type 1 diabetes reported gastrointestinal symp-
toms compared with 284/604 (47.0%, 95% CI 42.9 to 
51.1) controls, giving an OR of 1.9 (1.5–2.3, p<0.0001). 
The results of a further analysis of individual symptom 
frequencies and known medical conditions in people 
with type 1 diabetes compared with controls are shown 
in table 2.
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Table 3  Gastrointestinal symptom burden in people with type 1 diabetes compared with controls
Symptoms (n) Type 1 diabetes Controls OR 95% CI P values
0 216 278 0.52 0.41 to 0.65 <0.0001
1 171 169 0.82 0.64 to 1.1   NS
2 126 77 1.49 1.09 to 2.02 0.011
3 82 41 1.80 1.22 to 2.67 0.0028
4 55 20 2.67 1.46 to 4.17 0.0005
5 40 11 3.24 1.65 to 6.37 0.00028
6 10 8 1.07 0.42 to 2.73   NS
7 6 0 – – 0.034
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People with type 1 diabetes reported constipation in 
8.5% vs 3.3% in controls (OR 2.4), diarrhea in 6.1% vs 
2.6% in controls (OR 2.5) and alternating bowel habit 
in 8.8% vs 4.5% in controls (OR 2.1). This gave a cumu-
lative prevalence of 23.4% of such symptoms in people 
with type 1 diabetes compared with 10.4% for controls. 
Flatulence and bloating were common in both groups 
but significantly more so in people with type 1 diabetes. 
Tiredness and weight loss were also more common in 
people with type 1 diabetes and are often ascribed to 
insulin deficiency; however, the majority of individuals in 
this study had started insulin treatment for over a year. 
The only significant difference in gastrointestinal condi-
tions from controls was a history of pancreatitis (OR 
4.6) and ‘other’ conditions (OR 1.9). ‘Other’ conditions 
were self-reported as reflux, indigestion, H. pylori, hemor-
rhoids and previous surgery. When analyzing the prev-
alence of other underlying medical conditions, people 
with type 1 diabetes were more likely to have a history of 
anemia (OR 1.5), thyroid disease (OR 4.1), epilepsy (OR 
4.3) and neurologic disease (OR 2.4).
Table 3 shows the symptom burden for each group, 
showing that people with type 1 diabetes were signifi-
cantly less likely to have no gastrointestinal symptoms 
(OR 0.52) and that a higher proportion had a greater 
symptom burden compared with controls, particularly >3 
symptoms.
Quality of life and glycemic control
To determine the interactions between gastrointestinal 
symptoms, quality of life and glycemic control, data were 
stratified by reported symptoms, notably constipation, 
diarrhea, alternating bowel habit and abdominal pain. 
Figure 1A–D shows the quality of life scores for each 
symptom group.
Constipation
Sixty individuals with type 1 diabetes described constipa-
tion as did 20 individuals from the control population. 
The quality of life scores were significantly worse in those 
with type 1 diabetes and constipation overall (all p<0.01). 
When comparing individuals with type 1 diabetes and 
constipation with those with type 1 diabetes and normal 
bowel habit, the quality of life scores were significantly 
worse in all domains except for general health percep-
tions and social functioning. When comparing individ-
uals with type 1 diabetes and constipation and controls 
with constipation, the quality of life scores were signifi-
cantly worse in all domains except for social functioning, 
role limitations due to emotional problems and mental 
health composite score. Comparing individuals with type 
1 diabetes and constipation with controls with normal 
bowel habit, the quality of life scores were significantly 
worse in all domains (all p<0.01).
When comparing those with type 1 diabetes and consti-
pation with matched individuals with type 1 diabetes and 
normal bowel habit, there was no significant difference 
in HbA1c (8.2% (66 mmol/mol) vs 7.9% (62 mmol/
mol), p=0.45).
Diarrhea
Forty-three individuals with type 1 diabetes described 
diarrhea as did 16 individuals from the control popu-
lation. Individuals with type 1 diabetes and diarrhea 
had significantly worse scores in all domains compared 
with type 1 diabetes controls with normal bowel habit. 
Compared with controls with diarrhea, the quality of 
life scores were significantly worse in all domains except 
for bodily pain, mental health and physical composite 
score. Compared with controls with normal bowel habit, 
the quality of life scores were significantly worse in all 
domains except for bodily pain.
When comparing those with type 1 diabetes and diar-
rhea with matched individuals with type 1 diabetes and 
normal bowel habit, the median HbA1c was significantly 
worse (8.2% (66 mmol/mol) vs 7.3% (56 mmol/mol), 
p<0.001).
Alternating bowel habit
Sixty-two individuals with type 1 diabetes described 
alternating bowel habit as did 27 individuals from the 
control population. Individuals with type 1 diabetes and 
alternating bowel habit had significantly worse scores 
in all domains compared with type 1 diabetes controls 
with normal bowel habit. Compared with controls with 
alternating bowel habit, the quality of life scores were 
5BMJ Open Diab Res Care 2018;6:e000514. doi:10.1136/bmjdrc-2018-000514
Figure 1 (A) Quality of life scores in individuals with and without constipation. (B) Quality of life scores in individuals with 
and without diarrhea. (C) Quality of life scores in individuals with and without alternating bowel habit. (D) Quality of life scores 
in individuals with and without abdominal pain. BP, bodily pain; DM, diabetes mellitus; GH, general health perceptions; HC, 
healthy control; MCS, mental health composite score; MH, mental health; PCS, physical composite score; PF, physical 
functioning; RE, role limitations due to emotional problems; RP, role limitations due to physical health; SF, social functioning; 
VT, vitality.
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significantly worse in all domains except for bodily pain 
and physical composite score. Compared with controls 
with normal bowel habit, the quality of life scores were 
significantly worse in all domains. When comparing 
those with type 1 diabetes and alternating bowel habit 
with matched individuals with type 1 diabetes and 
normal bowel habit, the median HbA1c was significantly 
worse (8.5% (69 mmol/mol) vs 7.9% (62 mmol/mol), 
p=<0.001).
Abdominal pain
One hundred and twenty-six individuals with type 1 
diabetes described abdominal pain as did 81 individ-
uals from the control population. Individuals with type 
1 diabetes and abdominal pain had significantly worse 
scores only in the role limitations due to emotional prob-
lems, mental health and mental health composite score 
domains compared with type 1 diabetes controls without 
abdominal pain. Compared with controls with abdom-
inal pain, the quality of life scores were significantly 
worse in all domains except for bodily pain. Compared 
with controls without abdominal pain, the quality of life 
scores were significantly worse in all domains.
When comparing those with type 1 diabetes and 
abdominal pain with matched individuals with type 1 
diabetes without abdominal pain, the median HbA1c was 
significantly worse (8.25% (67 mmol/mol) vs 7.7% (61 
mmol/mol), p=0.0021).
Diabetes-related complications
The gastrointestinal questionnaire specifically asked 
about known complications of diabetes, including reti-
nopathy, nephropathy, neuropathy, arthropathy and 
gastric problems. Overall, 249 (35.3%) had retinopathy, 
55 (7.8%) had nephropathy, 133 (18.8%) had neurop-
athy, 82 (11.6%) had arthropathy and 35 (4.9%) had 
gastric problems.
To assess whether gastrointestinal symptoms were asso-
ciated with more complications of diabetes, comparison 
was made between frequencies of each complication 
stratified by symptom type. In those with normal bowel 
habit (n=515), the frequency of retinopathy, nephrop-
athy, arthropathy, neuropathy and gastric problems was 
32.6%, 6.0%, 9.5%, 15% and 1.7%, respectively.
Neuropathy was significantly more common in people 
with type 1 diabetes and any change in bowel habit. 
Retinopathy was associated with diarrhea and alter-
nating bowel habit but not constipation or abdominal 
pain. Nephropathy was associated with diarrhea and 
alternating bowel habit but not constipation or abdom-
inal pain. Joint problems were associated with diarrhea 
and alternating bowel habit but not constipation or 
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Table 4  Final diagnoses in those individuals with type 1 
diabetes and diarrhea
Diagnosis n (%)
Irritable bowel syndrome 34 (36.2)
Autonomic neuropathy 14 (14.9)*
Inflammatory bowel disease 10 (10.6)†
Celiac disease 9 (9.6)
Exocrine pancreatic disease 6 (6.4)‡
Small bowel bacterial overgrowth 5 (5.3)
Lactose intolerance 1 (1.1)
IgA deficiency 1 (1.1)
Diverticular disease 1 (1.1)
Peritoneal dialysis-related 1 (1.1)
Rectal cancer 1 (1.1)
Unclassified 11 (11.7)
*5 individuals had small bowel bacterial overgrowth on glucose 
hydrogen breath testing.
†7 ulcerative colitis, 2 Crohn’s disease and 1 microscopic colitis.
‡2 individuals had calcific pancreatitis on CT scanning (2 
individuals had celiac disease and chronic pancreatitis, 
2 individuals had celiac disease and inflammatory bowel disease, 
and 1 individual had celiac disease and autonomic neuropathy).
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abdominal pain. Gastric problems were associated with 
all bowel habit changes but most strongly with diarrhea.
Investigations
One hundred and five individuals with type 1 diabetes 
had diarrhea as a component of their symptoms (62 
with alternating bowel habit and 43 with diarrhea) and 
were contacted and offered further investigations. Of 
these 94 (92.2%) were willing to undergo the investiga-
tions as described in the Research design and methods 
section. The other 11 were either unwilling to be inves-
tigated or did not consider their symptoms signifi-
cant enough to undergo the proposed investigations. 
Table 4 shows the final diagnoses in this group following 
investigations.
Following assessment and investigation, 34/94 (36.2%, 
26.5–46.7) met the Rome III criteria for irritable bowel 
syndrome and were treated with antispasmodics and/
or low-dose antidepressants. Fourteen of 94 (14.9%, 
8.4–23.7) had autonomic neuropathy (5 of whom also 
had small bowel bacterial overgrowth and improved with 
antibiotics). Fourteen of 94 had positive celiac serology, 
of whom 9 had villous atrophy on biopsy (9.6%, 4.5–17.4) 
and commenced a gluten-free diet. Ten of 94 (10.6%, 
5.2–18.7) had inflammatory bowel disease (7 ulcerative 
colitis, 2 Crohn’s disease and 1 microscopic colitis) and 
were started on treatment. Six individuals had exocrine 
pancreatic disease (two with chronic pancreatitis on CT 
scan), all of whom improved on enzyme supplements. 
Overall, there was a change in management in 68/94 
(72.3%).
dIsCussIOn
This is the largest study of gastrointestinal symptoms in 
people with type 1 diabetes, in particular lower intes-
tinal symptoms. Overall, people with type 1 diabetes 
were almost twice as likely to describe gastrointestinal 
symptoms compared with controls, with about one in 
four (23.4%) describing constipation, diarrhea, or alter-
nating bowel habit. Furthermore, symptom burden was 
significantly higher compared with controls. Further 
analysis showed that diarrhea, constipation or alternating 
bowel habits were significantly more common compared 
with controls, as were symptoms such as flatulence and 
bloating, and were associated with poorer quality of life 
scores. Glycemic control was also significantly worse in 
those with diarrhea, abdominal pain or alternating bowel 
habits. Despite these symptoms, only a history of pancre-
atitis was significantly more common when comparing 
known gastrointestinal conditions. This may explain the 
constellation of abdominal pain, diarrhea, floating stools 
and weight loss, which could be attributed to exocrine 
pancreatic disease. Indeed, following investigation, 6.4% 
of people with type 1 diabetes and diarrhea were found to 
have exocrine pancreatic disease, including two individ-
uals with calcific pancreatitis. Both of whom had a history 
of significant alcohol intake for many years.
A further interesting finding was that gastrointestinal 
symptoms were associated with increased risk of diabe-
tes-related complications. Neuropathy and stomach 
problems were associated with any change in bowel habit, 
whereas diarrhea or alternating bowel habits were associ-
ated with increased risk of all diabetes-related complica-
tions. These findings are similar to the initial description 
of diabetic diarrhea by Bargen,4  in which peripheral 
neuropathy was frequently associated.
The association between gastrointestinal symptoms 
and poor glycemic control leads to a ‘chicken and egg’ 
hypothesis. From our data it is impossible to determine 
whether gastrointestinal symptoms lead to poor glycemic 
control, or whether poor glycemic control leads to gastro-
intestinal symptoms.
Importantly this study detected underlying gastroin-
testinal disorders in those with diarrhea. To date there 
are no published data examining the findings of inves-
tigations for diarrhea in a large cohort of people with 
type 1 diabetes. Irritable bowel syndrome accounted 
for around one-third of all people investigated, with 
autonomic neuropathy being the second most common 
positive finding. Not all of those with autonomic neurop-
athy had small bowel bacterial overgrowth according to 
glucose hydrogen breath testing, but this may represent 
false-negative results.31 Additionally, autonomic function 
was tested using cardiac function rather than intestinal 
motility or manometry studies. The correlation between 
cardiac autonomic dysfunction and intestinal autonomic 
dysfunction is not 100%.32 33 The finding of a high prev-
alence of inflammatory bowel disease is novel and has 
been confirmed in a recent study.34 
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Exocrine pancreatic disease is not unexpected and 
suggests that some people with diabetes may have been 
misclassified. A previous study by Hardt et al35 showed 
that around 10% of patients with type 1 or type 2 diabetes 
may actually have type 3c diabetes.28 The hypothesis is 
that patients present with diabetes-related symptoms for 
which they are treated, but they may have only subtle 
exocrine symptoms. Identification of these individ-
uals is likely to be important as other therapies may be 
required, such as pancreatic enzyme supplementation.35 
Furthermore, some of the newer medications such as the 
incretins may be more suitable for people with type 3c 
diabetes.
The frequency of some of the conditions identified 
initially appears questionable with high prevalence of 
both celiac disease and inflammatory bowel disease 
and low prevalence of lactose intolerance. However, all 
of these individuals had assessment for celiac disease 
and underwent colonoscopy, but assessment for lactose 
intolerance was not a first-line investigation, which would 
have reduced the overall prevalence. If an individual had 
a positive finding on the initial set of investigations, then 
further tests were not conducted.
The other diagnoses were expected except the finding 
of a rectal cancer. This individual was an older man who 
had started with looser motions over the previous few 
months. Colonoscopy revealed a significant lesion in the 
mid-rectum, which went on to be completely resected. A 
previous meta-analysis has shown that diabetes is a risk 
factor for colorectal cancer possibly due to hyperinsu-
linemia36 but is also associated with adverse outcomes 
following surgery for colorectal cancer.37 Our data suggest 
that diarrheal symptoms in people with type 1 diabetes 
deserve investigation before being ascribed nihilistically 
to autonomic neuropathy.
Despite this being such a large study with a suitable 
control group, there are a number of unanswered ques-
tions. This study was an epidemiologic study and not 
designed to establish mechanisms by which people with 
type 1 diabetes acquire gastrointestinal symptoms. Many 
of these symptoms were self-reported and not attributed 
to a formal diagnosis following investigations, for example, 
gastric problems. The focus of this study was however lower 
gastrointestinal symptoms. Despite this, the prevalence 
of gastrointestinal symptoms in the control group is in 
keeping with that of previous population-based studies.5 
The prevalence of underlying diagnoses was not compared 
with that in the control group as these individuals were 
not investigated and 11 individuals with type 1 diabetes 
declined investigations. However, this represents less than 
10% of those with type 1 diabetes and diarrhea and may 
represent symptom cycling.8 Additionally, initial assess-
ment did not take prescribed medications into account, 
which may be a confounder. In those undergoing further 
assessment for diarrhea, a full medication history was taken 
but were not felt to account for any gastrointestinal symp-
toms. Most of the cohort were young and not on other 
medications other than insulin. Several conclusions can be 
drawn in this regard as the prevalence of irritable bowel 
syndrome in the general population is known to be approx-
imately 15%. Our data support the theory that people with 
type 1 diabetes may perceive gastrointestinal symptoms 
more readily than people without diabetes suggested by the 
greater prevalence of gastrointestinal symptoms, including 
flatulence and bloating, as well as the increased preva-
lence of irritable bowel syndrome. Whether this is due to 
subtle changes in the autonomic nervous system or other 
intestinal hormones remains unclear. Previous studies 
have demonstrated that glycemic control has an effect 
on gastric function,15–19 but there are little data on lower 
gastrointestinal function. Confounding factors in previous 
studies have been the lack of investigation for underlying 
conditions, no face-to-face assessments and self-reporting 
of glycemic control.5 6 Additionally, previous studies have 
not assessed quality of life and, importantly, have not had a 
control group.
In conclusion, we have shown for the first time that 
lower gastrointestinal symptoms are common in type 1 
diabetes and have a significant effect on the quality of 
life and glycemic control. Investigation of patients with 
diarrhea had a high yield of treatable conditions, and 
therefore care for people with diabetes should encom-
pass gastrointestinal assessments routinely.
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